Genotypic analysis of XXXX 1a by sequencing of the @entity984 proteasic region in simeprevir therapy candidates.

@entity1 @entity3534 @entity3531 @entity984 @entity71634 @entity71631 @entity1098
UNASSIGNED: Each phase of the @entity3531 replication cycle can represent a therapy target. In fact, SIMEPREVIR (SMV) acts as @entity984 /4A protease inhibitor (PI); its efficacy is, however, reduced in HCV1a @entity1 characterized by NS3Q80K polymorphism. The aim of this work was to design a genotypic analysis of @entity984 protease in order to characterize viral quasispecies in @entity3531 1a @entity1 before starting the SMV therapy. In all, 38 peripheral blood- @entity1098 samples were collected from @entity1 infected with @entity3531 1a (RNA > 10,000 cp/ml). The samples were sequenced in a region of 543 nucleotides, codifying for 181 @entity3534 of the @entity984 protease with ABI PRISM 3130xl Genetic Analyzer (Applied Biosystems). Of the 38 samples, two showed the @entity71634 mutation associated with resistance to SMV. In 16 samples mutations associated with a possible resistance to protease inhibitor, TELAPREVIR, were observed. Only one sample showed the @entity71631 mutation, which is responsible for resistance to BOCEPREVIR, a protease inhibitor too. The data reported in this paper show a 5% prevalence of the @entity71634 mutation in @entity3531 1a @entity1 . So far, some differences in the percentage of the @entity71634 mutations were observed within the European population, when compared with its US counterpart. The prevalence study described herein, albeit observed on a low number of samples, could challenge the recommendations reported in the technical data sheet of SMV.
